Practice
Open Access
Screening for primary aldosteronism in primary care
Lisa Dubrofsky and Gregory L. Hundemer
CMAJ March 20, 2023 195 (11) E410; DOI: https://doi.org/10.1503/cmaj.221466
Lisa Dubrofsky
Division of Nephrology (Dubrofsky), Department of Medicine, Women’s College Hospital, Faculty of Medicine, University of Toronto, Toronto, Ont.; Division of Nephrology (Hundemer), Department of Medicine, and Ottawa Hospital Research Institute (Hundemer), University of Ottawa, Ottawa, Ont.
MDCMGregory L. Hundemer
Division of Nephrology (Dubrofsky), Department of Medicine, Women’s College Hospital, Faculty of Medicine, University of Toronto, Toronto, Ont.; Division of Nephrology (Hundemer), Department of Medicine, and Ottawa Hospital Research Institute (Hundemer), University of Ottawa, Ottawa, Ont.
MD MPHArticle Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Screening for primary aldosteronism in primary care
Lisa Dubrofsky, Gregory L. Hundemer
CMAJ Mar 2023, 195 (11) E410; DOI: 10.1503/cmaj.221466
Jump to section
- Article
- Primary aldosteronism (PA) is common among patients with hypokalemia and hypertension
- Patients with PA are at an increased risk of chronic disease if undiagnosed or untreated
- Expert consensus recommends screening for PA in high-risk populations
- Most antihypertensive medications can be continued during the work-up for PA
- An elevated aldosterone-to-renin ratio is suggestive of PA
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.
Podcast